Journal profile · Psychology

Psycho-Oncologie

ISSN 1778-3798 · eISSN 1778-381X · Lavoisier · FRANCE · Quarterly · Founded 2007

Psycho-Oncologie: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.44; hybrid open access; review over 12 weeks (community reports); community-reported acceptance: easy; 188 articles in 2025; indexed in SCIE and Scopus; the journal's website says submissions are paused or closed.

The journal's website says submissions are paused or closed: Psycho-Oncologie is now archived and no longer receiving submissions with this publisher. All articles published in the journal during its time with Springer will remain fully searchable through our websites. Source ↗Publisher website ·

Impact factor0.44Latest value listed by LetPub
CAS zoneZone 4 · Medicine2025 upgraded edition, major category · 2026 Xinrui edition Zone 4 · Medicine
Review timeover 12 weeksCommunity average
APC—No source gives fee information
AcceptanceEasyCommunity average
Articles per year1882025 · OpenAlex count

Scope

Aims, scope and focus

Psycho-Oncologie is published by Lavoisier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Health, Medicine and Society, Cancer survivorship and care and Psychoanalysis and Psychopathology Research, together about 42.6% of its articles. Its main subfields are General Health Professions. (generated from OpenAlex topic counts and CAS ranking data)

Research area (LetPub): Psychology

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. Health, Medicine and SocietyHealth Professions18.8%
  2. Cancer survivorship and careMedicine13.4%
  3. Psychoanalysis and Psychopathology ResearchPsychology10.4%
  4. Family Support in IllnessSocial Sciences8.2%
  5. Healthcare Systems and PracticesHealth Professions7.8%
  6. Childhood Cancer Survivors' Quality of LifeMedicine6.7%
  7. Social Policies and FamilySocial Sciences5.4%
  8. Palliative Care and End-of-Life IssuesMedicine5%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorOncologyZone 4
MinorPsychologyZone 4

Top journal: noReview journal: no

CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorOncologyZone 4
MinorPsychologyZone 4

Top journal: noReview journal: not marked

CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorOncologyZone 4
MinorPsychologyZone 4

Top journal: noReview journal: no

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

Impact factor
0.44LetPub ·
CiteScore 2026-06
0.5LetPub ·
SJR 2026-06
0.15LetPub ·
SNIP 2026-06
0.25LetPub ·
h-index
9LetPub ·
h-index
17OpenAlex ·
i10-index
59OpenAlex ·
2-year mean citedness
0.3OpenAlex ·
Self-citation rate
0%LetPub ·
Share of gold OA articles
81.32%LetPub ·

Volume

Articles per year
113LetPub ·

Articles by year OpenAlex count · 1,351 in total · the current year is incomplete

YearArticlesOpen accessCitations
20261381385
202518818834
2024424173
2023382943
2022372127
202129517

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Average review time (community reports)
over 12 weeksLetPub ·
Average acceptance (community reports)
EasyLetPub ·

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Hybrid open accessLetPub

A subscription journal in which authors can pay to publish their article open access.

No source has fee information yet; check the journal's website.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Profile

Publication details and official links

Publisher
Lavoisier
Country or region
FRANCE
Language
French
Frequency
Quarterly
Founded
2007
ISSN
1778-3798
Electronic ISSN
1778-381X
Official links

FAQ

Frequently asked questions about Psycho-Oncologie

What CAS zone is Psycho-Oncologie in?

In the 2025 upgraded edition of the CAS Journal Ranking, Psycho-Oncologie is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Psychology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.

What is the impact factor of Psycho-Oncologie?

The latest impact factor listed by LetPub is 0.44; CiteScore 0.5, h-index 17.

How long does peer review take at Psycho-Oncologie?

Authors report an average review time of over 12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

Which databases index Psycho-Oncologie?

According to LetPub and DOAJ records, Psycho-Oncologie is indexed in SCIE and Scopus.

Is Psycho-Oncologie open access, and what is the APC?

Psycho-Oncologie is a hybrid journal. Fee information is not available yet; check the journal's website.

Sources and updates

The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .